BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study

The Lancet Neurology

Fecha de publicación: Agosto de 2021

Autores: Irene Cortese, MD , Erin S Beck, MD, Omar Al-Louzi, MD, Joan Ohayon, MSN, Frances Andrada, MSN, Ikesinachi Osuorah, BS, Jenifer Dwyer, BSN, B Jeanne Billioux, MD, Nigar Dargah-zada, MD, Matthew K Schindler, MD, Kyle Binder, MD, Lauren Reoma, MD, Gina Norato, MSc, Yoshimi Enose-Akahata, PhD, Bryan R Smith, MD, Maria Chiara Monaco, PhD, Eugene O Major, PhD, Steven Jacobson, PhD, David Stroncek, MD, Steven Highfill, PhD, Sandhya Panch, MD, Daniel S Reich, MD, John Barrett, MD, Avindra Nath, MD, Pawel Muranski, MD

DOI: https://doi.org/10.1016/S1474-4422(21)00174-5

Background: Progressive multifocal leukoencephalopathy, a rare disease of the CNS caused by JC virus and occurring in immunosuppressed people, is typically fatal unless adaptive immunity is restored. JC virus is a member of the human polyomavirus family and is closely related to the BK virus. We hypothesised that use of partly HLA-matched donor-derived BK virus-specific T cells for immunotherapy in progressive multifocal leukoencephalopathy would be feasible and safe.